Search for a trial

The hysteroscopic morcellator versus the bipolar resectoscope for removal of larger intrauterine polyps: a randomized controlled trial.

To compare the HM to bipolar resectoscopy for removal of large intrauterine polyps in terms of efficiency and complications.

Safety and Efficacy of Embozene Microspheres for Uterine Fibroid
Embolization compared to Embosphere for Symptomatic Relief from Uterine Fibroids

The purpose of this clinical trial is to compare the safety and efficacy of Embozene® Microspheres for uterine fibroid embolization to Embosphere® for symptomatic relief from uterine fibroids.

The hysteroscopic morcellator versus the bipolar resectoscope for removal of submucous myomas: a randomized controlled trial.

To compare the HM to bipolar resectoscopy for removal of smaller type 0 and 1 myomas in terms of efficiency and complications.

A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist (leuprorelin 3.75mg) for pre-operative treatment of symptomatic uterine myomas.

Efficacy Objectives:- Primary objective of this study is to demonstrate non inferior efficacy of PGL4001 versus GnRH-agonist to reduce, prior to surgery, excessive uterine bleeding caused by uterine myomas.- Secondary objectives are to demonstrate…

TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): a randomized controlled trial

To investigate the effectiveness of imiquimod 5% cream for the treatment of CIN2-3 lesions, compared to LLETZ treatment and to assess long-term disease recurrence, side effects and quality of life associated with different treatment modalities.

Ulipristal versus Gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy: a double blind randomized controlled trial

Objective: to investigate if Ulipristal is non-inferior to GnRH in terms of intra-operative blood-loss (primary outcome), surgical time, surgical ease, complications, quality of life and costs.

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive Ovarian Cancer (UP-NEXT)

In this study, we look at how safe the new medicinal product XMT-1536 is for the treatment of ovarian cancer and how well it works. We compare the effect of XMT-1536 with the effect of a placebo. A placebo is a product without the active ingredient…